Patrys Limited (ASX: PAB)
Health Care · Biotechnology · AU
AU$0.03
+6.45% today · +10.0% 1Y
Patrys Limited (ASX: PAB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $15.77M and employs 15 people.
Over the last twelve months the share price has gained 10.0%, trading between 0.01 and 0.05.
Tweenvest scores Patrys Limited across four factors: quality 28/100, value 54/100, growth 0/100. Its strongest factor is value.
PAB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $15.77M
- Revenue (TTM)
- $66.95K
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 1.26
- 52-week high
- AU$0.05
- 52-week low
- AU$0.01
- Avg volume (3M)
- —
- Shares outstanding
- 666.61M
- Employees
- 15
- Next earnings
- —
About Patrys Limited
Based in Melbourne, Australia, Patrys Limited and its subsidiaries specialize in developing and commercializing advanced antibody technologies for cancer treatment. Their leading therapeutic, Deoxymab 3E10, is a distinctive DNA damage-repair antibody capable of penetrating cell nuclei. The company's pipeline also includes PAT-DX1, an antibody fragment specifically designed to target both primary and secondary brain cancers. Furthermore, Patrys is progressing PAT-DX3, a full-sized antibody that shares PAT-DX1's DNA-binding and DNA damage repair blocking properties, currently being evaluated for its tissue distribution and pharmacokinetic profile. Another promising development is PAT-DX1-NP, a product leveraging the targeted delivery of therapeutic payload-carrying nanoparticles directly into cancer cells. Patrys Limited was established in 2006.
- ISIN
- AU000000PAB9
- Founded
- 2006
- Listed since
- Jul 13, 2007
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.74 | -0.02% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.49 | -0.84% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.